362 related articles for article (PubMed ID: 11257652)
1. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy.
Holmäng S; Andius P; Hedelin H; Wester K; Busch C; Johansson SL
J Urol; 2001 Apr; 165(4):1124-8; discussion 1128-30. PubMed ID: 11257652
[TBL] [Abstract][Full Text] [Related]
2. Recurrence and progression in low grade papillary urothelial tumors.
Holmäng S; Hedelin H; Anderström C; Holmberg E; Busch C; Johansson SL
J Urol; 1999 Sep; 162(3 Pt 1):702-7. PubMed ID: 10458347
[TBL] [Abstract][Full Text] [Related]
3. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Navone R
Am J Surg Pathol; 2001 Dec; 25(12):1528-33. PubMed ID: 11717543
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome.
Sgambato A; Migaldi M; Faraglia B; De Aloysio G; Ferrari P; Ardito R; De Gaetani C; Capelli G; Cittadini A; Trentini GP
Int J Cancer; 2002 Feb; 97(5):671-8. PubMed ID: 11807796
[TBL] [Abstract][Full Text] [Related]
6. Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder.
Ramos D; Navarro S; Villamón R; Gil-Salom M; Llombart-Bosch A
Cancer; 2003 Apr; 97(8):1876-83. PubMed ID: 12673713
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973).
March-Villalba JA; Ramos-Soler D; Soriano-Sarrió P; Hervás-Marín D; Martínez-García L; Martínez-Jabaloyas JM
Urol Oncol; 2019 Feb; 37(2):158-165. PubMed ID: 30446453
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification.
Santos L; Amaro T; Costa C; Pereira S; Bento MJ; Lopes P; Oliveira J; Criado B; Lopes C
Int J Cancer; 2003 Jun; 105(2):267-72. PubMed ID: 12673690
[TBL] [Abstract][Full Text] [Related]
9. High Grade T1 Papillary Urothelial Bladder Cancer Shows Prominent Peritumoral Retraction Clefting.
Džombeta T; Krušlin B
Pathol Oncol Res; 2018 Jul; 24(3):567-574. PubMed ID: 28752222
[TBL] [Abstract][Full Text] [Related]
10. Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center.
Miyamoto H; Brimo F; Schultz L; Ye H; Miller JS; Fajardo DA; Lee TK; Epstein JI; Netto GJ
Arch Pathol Lab Med; 2010 Aug; 134(8):1160-3. PubMed ID: 20670136
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
Chang WC; Chang YH; Pan CC
Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic study of 60 cases of urothelial neoplasms with inverted growth patterns: Reclassification by international consultation on urologic disease (ICUD) recommendations.
Bang H; Park H; Park S; Choi E; Cho MS; Sung SH; Choi SY; Cho YM; Jeong SU; Ro JY
Ann Diagn Pathol; 2020 Feb; 44():151433. PubMed ID: 31785538
[TBL] [Abstract][Full Text] [Related]
13. Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center.
Lee TK; Chaux A; Karram S; Miyamoto H; Miller JS; Fajardo DA; Epstein JI; Netto GJ
Hum Pathol; 2011 Nov; 42(11):1799-803. PubMed ID: 21777949
[TBL] [Abstract][Full Text] [Related]
14. Survival following the diagnosis of noninvasive bladder cancer: WHO/International Society of Urological Pathology versus WHO classification systems.
Schned AR; Andrew AS; Marsit CJ; Zens MS; Kelsey KT; Karagas MR
J Urol; 2007 Oct; 178(4 Pt 1):1196-200; discussion 1200. PubMed ID: 17698105
[TBL] [Abstract][Full Text] [Related]
15. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia.
Desai S; Lim SD; Jimenez RE; Chun T; Keane TE; McKenney JK; Zavala-Pompa A; Cohen C; Young RH; Amin MB
Mod Pathol; 2000 Dec; 13(12):1315-23. PubMed ID: 11144928
[TBL] [Abstract][Full Text] [Related]
16. Quantitative molecular grading of bladder tumours: a tool for objective assessment of the biological potential of urothelial neoplasias.
Bollmann D; Bollmann M; Bankfalvi A; Heller H; Bollmann R; Pajor G; Hildenbrand R
Oncol Rep; 2009 Jan; 21(1):39-47. PubMed ID: 19082441
[TBL] [Abstract][Full Text] [Related]
17. Histologic grading of urothelial carcinoma: a reappraisal.
Cheng L; MacLennan GT; Lopez-Beltran A
Hum Pathol; 2012 Dec; 43(12):2097-108. PubMed ID: 22542126
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
19. Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up.
Yin H; Leong AS
Am J Clin Pathol; 2004 May; 121(5):679-87. PubMed ID: 15151208
[TBL] [Abstract][Full Text] [Related]
20. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?
Hentschel AE; van Rhijn BWG; Bründl J; Compérat EM; Plass K; Rodríguez O; Henríquez JDS; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Scavarda-Lamberti A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Cohen D; Lunelli L; Cussenot O; Sheikh SE; Volanis D; Coté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Babjuk M; van der Kwast TH; Sylvester RJ
Urol Oncol; 2020 May; 38(5):440-448. PubMed ID: 31704141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
